华丽家族称增资海和药物暨关联交易的事项尚在进行中

Core Viewpoint - The stock of Huayi Family (600503) experienced an abnormal fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days [1] Group 1: Company Announcement - Huayi Family announced that its cash investment in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. is still ongoing, which involves related party transactions [1] - The investment decision is based on strategic planning and the development prospects of the biopharmaceutical industry [1] Group 2: Future Considerations - The company acknowledges that future actual conditions, such as changes in policies, market environments, competitive situations, and factors related to Haihe Pharmaceutical, may impact its operational performance [1] - Insufficient understanding and tracking of the biopharmaceutical industry could lead to challenges in post-investment management and empowerment, potentially affecting investment returns [1]